Article Text

Download PDFPDF
p63 Protein expression in high risk diffuse large B-cell lymphoma
  1. A E Hallack Neto1,
  2. S A C Siqueira2,
  3. F L Dulley1,
  4. M A Ruiz1,
  5. D A F Chamone1,
  6. J Pereira1
  1. 1Haematology Services, Clinical Hospital of São Paulo University, São Paulo, Brazil
  2. 2Pathology Services, Clinical Hospital of São Paulo University, São Paulo, Brazil
  1. Dr A E Hallack Neto, Oscar Vidal 90, 36010-060, Juiz de Fora, Minas Gerais, Brazil; abrahallack{at}


Background: p63 gene is a p53 homologue that encodes proteins with transactivation, DNA-binding and tetramerisation domains. The isoforms TAp63 and TAp73 transactivate p53 target genes and induce apoptosis, whereas the isoforms ΔNp63 and ΔNp73 lack transactivation and might have dominant-negative effects in p53 family members. p63 is expressed in germinal centre lymphocytes and can be related to the development of the lymphoma, but the prognostic significance of its expression in the survival of patients with diffuse large B-cell lymphoma (DLBCL) remains unclear.

Aims: To determine whether quantitative immunohistochemical (IHC) analysis of p63 protein expression correlates with CD10 antigen, Bcl-6 antigen and IRF4 antigen expression and to determine whether p63 is a surrogate predictor of overall survival in high–intermediate and high risk DLBCL populations.

Methods: CD10, Bcl-6 and IRF4 expression were retrospectively evaluated by IHC in 73 samples of high–intermediate and high risk DLBCL and were used to divide the lymphomas into subgroups of germinal centre B-cell-like (GCB) and activate B-cell-like (ABC) DLBCL. Similarly, p63 expression was evaluated by IHC and the results were compared with subgroups of DLBCL origin and with the survival rates for these patients.

Results: p63 was expressed in more than 50% of malignant cells in 11 patients and did not show correlation with subgroups of GCB-like DLBCL or ABC-like DLBCL, but p63(+) patients had better disease-free survival (DFS) than those who were negative (p = 0.01).

Conclusions: p63(+) high–intermediate and high risk DLBCL patients have a better DFS than negative cases.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: This work was supported by the “Fundação Faculdade de Medicina” of Sao Paulo University.

  • Competing interests: None.

  • Ethics approval: Ethics approval was obtained.